TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07482423: XVIE to Treat Androgenetic Alopecia (AGA)

Sponsor: Restore Biologics Holdings, Inc. dba Xtressé · Phase: PHASE1/PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 30 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$394,740

Rescue Site Savings

+$263,160

Unlock Full NCT07482423 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07482423 Rescue Dossier →